Skip to main content

Table 1 Clinical characteristics of CLL patients and RNA sequencing read count data

From: Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens

 

Age sex, Rai stage, total WBC count (cumm3)

% cells CD38+

Zap-70 status

Specimen

Normal CD19+ B cells

   

B1

   

B2

   

B3

   

B4

   

B5

U-CLL

67 M, stage II, 40,000

0 %

neg

CLL6

88 M, stage III, 90,000

59 %

pos

CLL9

62 M, stage I, 96,000

24 %

pos

CLL25

71 M, stage II, 135,000

8 %

pos

CLL28

56 M, stage II, 102,000

55 %

pos

CLL40

68 M, stage IV, 320,000

50 %

pos

CLL44

M-CLL

55 M, stage III, 37,000

0 %

ND

CLL26

61 M, stage 0, 24,000

5 %

neg

CLL32

64 M, stage I, 28,000

0 %

pos

CLL37

78 M, stage III, 98,000

0 %

neg

CLL39

  1. (neg, negative, pos, positive, ND, not done, M-CLL mutated IGVH, U-CLL non-mutated IGVH)